Kiora Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On 07 de nov. de 2025, KPRX reported earnings of 0.01 USD per share (EPS) for Q3 25, beating the estimate of -0.74 USD, resulting in a 101.33% surprise. Revenue reached --, compared to an expected 765.00 mil, with a -100.00% difference. The market reacted with a +0.43% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analistas forecast an EPS of -0.68 USD, with revenue projected to reach 1.53 milhão USD, implying an diminuir of -6900.00% EPS, and -- of --% in Revenue from the last quarter.
FAQ
What were Kiora Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Kiora Pharmaceuticals, Inc. Common Stock reported EPS of $0.01, beating estimates by 101.33%, and revenue of $0.00, -100% below expectations.
How did the market react to Kiora Pharmaceuticals, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 0.43%, changed from $2.32 before the earnings release to $2.33 the day after.
When is Kiora Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for 23 de mar. de 2026.
What are the forecasts for Kiora Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 3
analistas, Kiora Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of $1.53M for Q4 2025.